MiNK Reports Early Phase 2 Day‑28 Survival and Clinical Signals for Off‑the‑Shelf iNKT Therapy

Overview

• MiNK presented initial observations on Thursday, Aug. 6 at MHSRS that the first patients treated with agenT‑797 in its randomized Phase 2 study were alive at Day 28 with better oxygenation, mental status, hemodynamics and control of baseline infections.
• The C‑1300‑02 trial is a randomized Phase 2 study comparing agenT‑797 plus standard care to placebo plus standard care and began dosing at the First Lviv Territorial Medical Union with authorization from the Ukraine Ministry of Health and an active U.S. IND.
• MiNK reported no major serious adverse events attributed to agenT‑797 in the first treated patients, while blood and bronchoalveolar lavage tests showed reduced inflammatory markers and signals consistent with immune and tissue repair.
• AgenT‑797 is a cryopreserved, allogeneic invariant natural killer T (iNKT) cell therapy that can be dosed from inventory without apheresis, patient‑specific manufacturing, HLA matching or lymphodepletion, a feature the company says enables rapid use in resource‑limited or conflict settings.
• MiNK will give a corporate and clinical update, including details on a named‑patient program, when it reports Q2 results on Aug. 13 and it expects preliminary Phase 2 data in the second half of 2026 with more data into early 2027.